To receive Noxxon’s real time information, please send a request to This email address is being protected from spambots. You need JavaScript enabled to view it.

 



Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. NOXXON disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all

DateTitelDownload

2015, April 23Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets

2014, June 02NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

2014, April 04NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

2013, July 24NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

2012, June 19NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

2010, July 7NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36

2009, October 12NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36

2009, June 8NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer